This division indicated that renal cancer, liver cancer, and stomach cancer patients in the RADIL high-expression group had poor outcomes, while patients in the RADIL low-expression group had a better OS (P < 0.001, Figures 4B,D,F). This evidence concerns the gene RADIL and renal carcinoma.